prednisolone has been researched along with Atheroma in 5 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are under evaluation." | 5.43 | Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. ( Alaarg, A; Dallinga-Thie, GM; de Winther, M; Hamers, AA; Laudes, M; Lutgens, E; Meiler, S; Metselaar, JM; Mulder, WJ; Schulte, DM; Seijkens, T; Stroes, ES; Tang, J; Van den Bossche, J; van der Valk, FM; Zheng, KH, 2016) |
| " Our paper details the first clinical studies of a liposomal nanoparticle encapsulating prednisolone (LN-PLP) in atherosclerosis." | 5.20 | Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. ( Calcagno, C; Dallinga-Thie, GM; Fayad, ZA; Legemate, DA; Lobatto, ME; Mani, V; Metselaar, JM; Mulder, WJ; Nederveen, AJ; Nieuwdorp, M; Otten, MJ; Paridaans, MP; Ramachandran, S; Schulte, DM; Storm, G; Stroes, ES; van der Valk, FM; van Wijk, DF; Verberne, HJ; Willems, MC, 2015) |
| " History of lupus nephritis and a higher average dose of prednisolone used since diagnosis were associated with cIMT progression in patients." | 3.96 | Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisol ( Ajeganova, S; Frostegård, J; Gustafsson, T; Hafström, I; Lindberg, L, 2020) |
| "Atherosclerosis is a lipid-driven inflammatory disease, for which nanomedicinal interventions are under evaluation." | 1.43 | Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. ( Alaarg, A; Dallinga-Thie, GM; de Winther, M; Hamers, AA; Laudes, M; Lutgens, E; Meiler, S; Metselaar, JM; Mulder, WJ; Schulte, DM; Seijkens, T; Stroes, ES; Tang, J; Van den Bossche, J; van der Valk, FM; Zheng, KH, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ajeganova, S | 1 |
| Gustafsson, T | 1 |
| Lindberg, L | 1 |
| Hafström, I | 1 |
| Frostegård, J | 1 |
| van der Valk, FM | 3 |
| van Wijk, DF | 1 |
| Lobatto, ME | 1 |
| Verberne, HJ | 1 |
| Storm, G | 2 |
| Willems, MC | 1 |
| Legemate, DA | 1 |
| Nederveen, AJ | 1 |
| Calcagno, C | 1 |
| Mani, V | 1 |
| Ramachandran, S | 1 |
| Paridaans, MP | 1 |
| Otten, MJ | 1 |
| Dallinga-Thie, GM | 2 |
| Fayad, ZA | 1 |
| Nieuwdorp, M | 1 |
| Schulte, DM | 3 |
| Metselaar, JM | 3 |
| Mulder, WJ | 2 |
| Stroes, ES | 3 |
| Meiler, S | 1 |
| Tang, J | 1 |
| Zheng, KH | 2 |
| Van den Bossche, J | 1 |
| Seijkens, T | 1 |
| Laudes, M | 1 |
| de Winther, M | 1 |
| Lutgens, E | 1 |
| Alaarg, A | 2 |
| Hamers, AA | 2 |
| da Silva, AE | 1 |
| Versloot, M | 1 |
| van Ufford, LC | 1 |
| Arida, A | 1 |
| Protogerou, AD | 1 |
| Konstantonis, G | 1 |
| Fragiadaki, K | 1 |
| Kitas, GD | 1 |
| Sfikakis, PP | 1 |
1 trial available for prednisolone and Atheroma
| Article | Year |
|---|---|
Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.
Topics: Administration, Intravenous; Adult; Aged; Anti-Inflammatory Agents; Arteries; Atherosclerosis; Femal | 2015 |
4 other studies available for prednisolone and Atheroma
| Article | Year |
|---|---|
Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisol
Topics: Adult; Aged; Cardiovascular Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Case- | 2020 |
Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis.
Topics: Animals; Atherosclerosis; Humans; Liposomes; Macrophages; Mice; Plaque, Atherosclerotic; Prednisolon | 2016 |
Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Cell Proliferation; Cytokines; Endoplasmic Retic | 2016 |
Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atherosclerosis; Biological Factors; Carotid Artery Dis | 2017 |